Claris Lifesciences Limited, a BSE listed company, is a multi-business enterprise and the Holding Company of Claris Injectables – a wholly owned subsidiary dealing in Specialty Injectables business, collectively ‘Claris’; and Claris Otsuka – a Joint Venture with Japanese Otsuka Pharmaceutical Factory, Inc. & Mitsui & Co. Ltd. for Infusion business in India and emerging markets. Coupled with its strength of technical knowhow and expertise in manufacturing and marketing injectables products, Claris, today, stands as a world-class organisation, built on entrepreneurial culture and product quality through emotional pharmacopoeia.
BLAZE TO BRILLIANCE
Established in 1999, the company manifested its strength through generic injectables segment. Today, Claris has its presence across more than 100 countries worldwide, and majority of the business is generated through export to the global markets. The company manufactures and markets niche, high-end, and technically-complex products across multiple delivery systems and therapeutic segments. With over 1,300 employees, Claris is in a position to reap the rewards for its unparalleled collective knowledge expertise. Its state-of-the-art manufacturing facilities, with ISO 9001-2000 and WHO GMP certifications, and US FDA approval, act as the backbone to the overall business of the company.
The USP of the brand exemplifies commitment to quality excellence with several foreign regulatory approvals on hand, including US FDA, MHRA (UK), TGA (Australia), MCC (South Africa), ANVISA (Brasil), INVIMA (Colombia), and GCC FDCA. A customer-centric company with technology-driven processes, Claris advances to offer world-class products to its patients, globally. With several of its products enjoying global recognition, the company has ambitious plans in place for the USA market. Claris believes in bringing world-class, life-saving, progressive, and sustainable products in the market with an unrelenting focus on quality.
ENGAGEMENT THAT ENTHRALLS
Claris works with a vision to be one of the world’s most admired pharmaceutical companies in the global generics industry. A significant majority of its products are generic drugs, capable of being directly injected into the human body, and predominantly used in the treatment of critical illnesses; hence, the quality of the products has remained a nonnegotiable healthcare output for the company throughout its journey. The growth of the company is escalated with the support of a team of scientists, experts, and management professionals, who work diligently to cater to customers, taking the organisation to newer heights year-on-year.
The company projects expertise in developing complex technologies across multiple delivery systems. At Claris, the innovation process is carefully mapped out, and has proved instrumental in the growth of the company. The company seeks to imbue innovation through formulation studies, method development and validation, and study on container closure systems. It is one of a few companies to develop Parenteral Fat Emulsion, specific bulk drugs, and UniKit – a unique and significant delivery system for drywet injectable combination. NDDS (Novel Drug Delivery System), the company’s thrust area, is capable of offering significant breakthroughs in the healthcare industry.
Claris is committed to continuously scale-up its efforts and resources in bringing innovative & affordable medical care products to patients worldwide, thereby contributing to the well-being of Earth’s most precious resource – human lives. With a primary concern for the quality of the products, the company believes in proffering responsibility beyond business commitments. Over the years, Claris has supported several social causes aimed at promoting sports, health, education, and culture, encompassing the broader spectrum of the society.